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 A BSTRACT 
 Drug-induced hypersensitivity reactions are instructive 
examples of immune reactions against low molecular weight 
compounds. Classically, such reactions have been explained 
by the hapten concept, according to which the small antigen 
covalently modifi es an endogenous protein; recent studies 
show strong associations of several HLA molecules with 
hypersensitivity. In recent years, however, evidence has 
become stronger that not all drugs need to bind covalently 
to the major histocompatibility complex (MHC)-peptide 
complex in order to trigger an immune response. Rather, 
some drugs may bind reversibly to the MHC or possibly to 
the T-cell receptor (TCR), eliciting immune reactions akin 
to the pharmacological activation of other receptors. While 
the exact mechanism is still a matter of debate, noncovalent 
drug presentation clearly leads to the activation of drug-
 specifi c T cells. In some patients with hypersensitivity, such 
a response may occur within hours of even the fi rst exposure 
to the drug. Thus, the reaction to the drug may not be the 
result of a classical, primary response but rather be mediated 
by existing, preactivated T cells that display cross-reactivity 
for the drug and have additional (peptide) specifi city as well. 
In this way, certain drugs may circumvent the checkpoints 
for immune activation imposed by the classical antigen pro-
cessing and presentation mechanisms, which may help to 
explain the idiosyncratic nature of many drug hypersensi-
tivity reactions. 
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 INTRODUCTION 
 Adverse effects to drugs are a common incidence for the 
clinician. Most reactions are caused by the pharmacological 
or toxicological activities of the drug and are generally 
 predictable (type A). However, nonpredictable, idiosyncratic 
(type B) reactions 1 , 2 may occur as well, amounting to ~15% 
of all cases. Most of the type-B reactions are mediated by the 
immune system and thus also termed drug-hypersensitivity 
reactions. Elicited by different immune mechanisms, they 
can become manifest as many distinct diseases. 3 , 4 Often, the 
pathological mechanisms of these immune-mediated adverse 
effects are not completely clear. Some reactions are of the 
immediate type and are clearly mediated by antibodies. 5 
However, more recent studies by different groups clearly 
show that patients with drug hypersensitivity harbor drug 
specifi c T cells in their peripheral blood and in the affected 
tissues. 6-8 The functions of these drug-specifi c T cells seem 
to determine the clinical picture of the disease. 9 
 Drug-induced hypersensitivity reactions are fascinating dis-
eases, as a small chemical compound can elicit a strong sys-
temic immune reaction. These diseases can also be seen as 
 “ experimental models ” of nature, with the physician per-
forming an unintended — albeit instructive — “ experiment. ” 
By dissecting the underlying mechanisms, novel insights 
can be gained from these experiments not only about drug-
hypersensitivity reactions in particular, 1-3 but also about 
immune reactions in general. 
 THE HAPTEN AND PROHAPTEN CONCEPT 
 How do small compounds such as drugs stimulate T cells? 
An answer to this question is certainly required to under-
stand the side effects observed, and possibly allow for the 
prediction of these reactions based on the characteristics of 
the drug. For a long time, the  “ immunological dogma ” pos-
tulated that small, low-molecular weight compounds per se 
are not capable of eliciting an immune response. In order 
for an immune reaction to occur, APC have to take up and 
process complex and large antigens and, subsequently, pres-
ent these to T cells. However, small compounds such as drugs 
or metal ions were found to be able to trigger an immune 
response nevertheless. The hapten (and prohapten) model is 
currently the accepted explanation for these observations. 
Chemically reactive, small compounds (ie, haptens) bind to 
proteins or peptides and modify them. 10-12 These are then 
processed and presented as hapten-modifi ed peptides to T 
cells, which can react with the hapten antigen. Alternatively, 
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haptens may also bind to immune molecules that are involved 
in the presentation process, such as the major histocompati-
bility complex (MHC) itself. 13 , 14 Prohaptens are a variation 
on the same theme: in order to become chemically reactive, 
they fi rst need to be converted into a hapten by being metab-
olized into a compound that is chemically reactive. 1 , 2 , 15 , 16 
 EVIDENCE FOR THE EXISTENCE OF 
NONCOVALENT HAPTENS 
 The (pro)hapten concept elegantly circumvents the (pre-
sumed) blindness of the immune system for low molecular 
weight compounds by postulating that chemical reactivity 
and subsequent coupling to a macromolecule carrier is an 
absolute necessity. As a consequence, drugs and other sub-
stances that are incapable of such conjugation with a carrier 
would not be antigens and could not induce hypersensitivity 
reactions. However, there is clear clinical, immunological, 
and biochemical evidence to the contrary ( Table 1 ). 
 The parental, not metabolized forms, of several different 
drugs are able to stimulate T cells via the T-cell receptor 
(TCR) in an MHC-dependent way, in particular lamo-
trigine, 7 carbamazepine, 8 sulfamethoxazole (SMX), 17 , 18 
mepivacaine, 19 lidocaine, 19 , 20 p-phenylendiamine, 21 and 
radio-contrast media (RCM), 38 , 39 even though most of them 
have known metabolites that can, in principle, act as hap-
tens or are known to do so. SMX has been characterized 
particularly well, as its reactive metabolite SMX-nitroso 
(SMX-NO), acting as a typical hapten, was available for 
comparison. 23 , 24 Hypersensitivity to the drug SMX was 
thought to be a consequence of bioactivation to the hydrox-
ylamine metabolite (SMX-NHOH) and further oxidation to 
the ultimate, reactive metabolite SMX-NO. The antioxidant 
glutathione is known to protect cells from reactive metabo-
lites by conjugation and subsequent dissociation to SMX-
NHOH and/or SMX. 24 However, only a minority of T-cell 
clones (TCC) derived from SMX-allergic patients reacted 
with the chemically reactive metabolite. 25 Most surpris-
ingly, addition of glutathione to peripheral blood mononu-
clear cells enhanced rather than reduced the proliferation of 
T cells in response to SMX-metabolites, 26 presumably by 
transforming SMX-NO back to the  “ original ” antigen, 
SMX. The response of SMX-NO-specifi c TCC was abro-
gated when glutathione was present during the covalent 
modifi cation of APC. Collectively, these experiments sup-
port the concept that some T cells in allergic individuals 
recognize the noncovalently bound parent drug SMX rather 
than APC covalently modifi ed by SMX-NO. 25 , 26 
 For several drugs, the kinetics of in vitro T-cell activation 
are simply much too fast for any involvement of antigen 
processing. In the presence of APC, lidocaine and SMX 
activate T cells quasi immediately as revealed by a rapid 
and sustained intracellular Ca 2+ increase. 18 It is impossible 
to reconcile this timing with an intermediate metabolism 
and processing step, which needs 60 minutes or longer to 
occur. Also, the kinetics of TCR down-regulation on drug 
reactive TCC after encountering the inert drug are similar to 
the recognition of preprocessed, immunogenic peptides 
(occurring within the fi rst 30 minutes) and clearly differ 
from the recognition of proteins, which requires several 
hours. 18 Several other observations argue against process-
ing or covalent binding. For several drugs, specifi c TCC 
reacted even if the APC were fi xed by glutaraldehyde, 
excluding the involvement of either processing or intracel-
lular metabolism. 7 , 8 , 17-19 Further, and at least for SMX, 
covalent binding is not necessary. Upon pulsing of APC, 
 Table 1.  The p-i Concept: Evidence Pro and Contra* 
 PRO 
Numerous TCC specifi c for the parental form of several drugs despite the existence of reactive metabolites 7 , 8 , 17-21 
Glutaraldehyde-fi xed APC can still present drug 7 , 8 , 17-19 , 22 
Washing removes drug and prevents T-cell activation 17 , 22 
Kinetics of TCR down-regulation too fast to allow antigen processing 18 
Kinetics of Ca 2+ mobilization too fast to allow antigen processing 18 
Inhibition of SMX-NO generation by glutathione increases drug presentation 23-26 
High incidence of unrestricted, drug-reactive clones 27 
Elevated frequency of alloreactive drug-reactive clones compared with peptide-specifi c TCC 28 
Exchange or removal of MHC-class-II-associated peptides does not affect drug presentation 29 
Kinetics of ERK phosphorylation too fast to allow antigen processing 22 
 CONTRA 
Clearly established for chemically reactive drugs 10-14 
Delayed nature of majority of reactions; induction of a primary response is possible 10-14 
Strong associations between several MHC-class-I alleles and drug hypersensitivity 30-37 
 *TCC indicates T-cell clone; APC, antigen-presenting cell; TCR, T-cell receptor; SMX-NO, sulfamethoxazole-nitroso; MHC, major 
histocompatibility complex; and ERK, extracellular signal-related kinase. 
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which removes the drug (incubation of APC with the drug 
for 1 hour followed by 2 washing steps), no T-cell stimula-
tion was observed, while the hapten SMX-NO, capable of 
covalently modifying the MHC peptide complex, was still 
able to stimulate hapten-reactive T cells. 17 Many drug-
 specifi c TCC were found to be MHC-unrestricted, 27 and the 
frequency of alloreactive TCC is much higher among drug- 
than peptide-specifi c TCC from the same donor. 28 Last, the 
MHC-bound peptide seems to be irrelevant for SMX-
 specifi c T-cell activation. 29 
 Despite these unusual characteristics, T-cell activation by 
such drugs is TCR-dependent nevertheless, as recently 
shown using drug-specifi c TCR transfectants. 22 Two SMX-
specifi c human TCR were introduced into the mouse T-cell 
hybridoma cell line 54  17 (O. Acuto, personal communica-
tion, January 2003), according to the method described by 
Vollmer et al. 40 These transfectants expressed drug-specifi c 
TCR on the cell-surface and could be stimulated in a spe-
cifi c way in the presence of APC, resulting in interleukin 2 
(IL-2) secretion. Key fi ndings with these transfectants, 
which corroborated the previous observations with drug-
specifi c TCC, were that the drug can be washed away (con-
trary to haptens covalently bound to carrier molecules), that 
the presence of APC (MHC) is required for IL-2 production, 
and that fi xed APC are still able to present the drug. Simi-
larly, the kinetics of TCR activation were too fast to involve 
antigen processing, as antigen-dependent extracellular 
signal-related kinase (ERK) phosphorylation was detected 
within 1 minute of SMX exposure. 
 THE P-I CONCEPT: THE TCR AS THE ANTIGEN 
BINDING MOLECULE? 
 Clearly, the hapten concept does not suffi ce to account for 
all the above observations. As a consequence, we have 
recently proposed a third model, which is not meant to 
 contradict but rather to supplement the hapten/prohapten 
concept. Termed the p-i concept, which stands for  “ direct 
pharmacological interaction of drugs with immune recep-
tors, ” 41 it states that certain drugs bind specifi cally and 
reversibly to some of the highly variable antigen-specifi c 
TCR in a direct way, instead of covalently modifying the 
MHC-peptide complex, which are the 2 feasible  “ partners ” 
to accommodate allergy-inducing drugs. Such a drug-TCR 
interaction would be independent of metabolism and pro-
cessing and, in fact, mimic drug interactions with other, 
nonimmunological receptors. While the MHC-peptide com-
plex would not contribute (much) to the binding energy, it 
would still be necessary for full T-cell activation. Why do 
we think the TCR to be the more likely candidate for drug 
binding than the MHC, which is the  “ traditional ” antigen-
binding receptor? 
 The mere idea may appear far-fetched at fi rst, but such a 
mechanism seems nevertheless feasible in principle, and at 
least one precedent has already been reported. Divalent 
Nickel ions (Ni) are generally considered haptens even 
though they do not bind to proteins covalently but rather 
by forming reversible coordination complexes. 42 Weltzien 
and coworkers identifi ed and characterized an HLA-DR-
promiscuous, Ni-specifi c TCR in which Ni interacts simul-
taneously with the MHC and TCR by making contacts 
with a conserved His81 in the HLA-DR   -chain as well as 
Tyr29 and Tyr94 in CDR1  of the TCR. Thus, Ni forms a 
bridge between both receptors, much like a superantigen, 
even though requiring idiotypic residues in the TCR. 13 Ni 
has 6 coordination sites, of which only 3 are known for this 
complex at present. Nevertheless, a substantial part of its 
binding energy will be derived by the 2 (at least) contacts 
with the TCR of this complex. In fact, Ni binding may rep-
resent a  “ compromise ” between how a typical hapten and a 
small antigen incapable of covalent binding may interact 
with the MHC and the TCR (see  Figure 1 and legend for a 
detailed explanation). 
 For haptens, the majority of the antigen binding energy 
stems from the interaction with the MHC-peptide complex 
via few but strong covalent bonds (hapten; note that certain 
haptens may be strongly associated not only with the MHC 
but also the TCR 43 ). Ni may interact either like a noncova-
lent hapten 14 or, as depicted here, 13 forming equally strong, 
noncovalent interactions with both MHC and TCR (nickel), 
while at least some drugs would derive the majority of their 
binding energy from weak, noncovalent interactions with 
the TCR (p-i concept). These different modes of interaction 
represent a continuum of possibilities, with the (pro)hapten 
mode on one extreme of the spectrum, the p-i-concept mode 
representing the other extreme, and the Ni mode as an inter-
mediate possibility. 
 Consider as well that    TCR are peptide receptors. It has 
been known for 30 years that drugs can activate receptors 
that have peptides or proteins as endogenous receptors, the 
classical example being the opiate alkaloids. For these as 
 Figure 1.   A schematic representation of how the TCR and the 
MHC might accommodate an antigen according to different 
models. The antigen (metal ion or drug) is depicted as a black 
ball, covalent bonds are indicated by bold lines, and noncovalent 
interactions by thin, dashed lines. 
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well as many other serpentine receptors, a myriad of com-
pounds are known to bind and evoke many pharmacologi-
cally different responses. More recently, nonpeptide agonists 
have also been found for tyrosine kinases as well as growth 
factor and cytokine receptors. 44 However, apart from a 
hydrophobic cleft between the CDR3  and CDR3  regions, 
the TCR does not feature a  “ suitable ” binding pocket or 
groove for small molecular weight compounds such as 
 peptide receptors. Still, it cannot be excluded categorically 
that some drugs may bind to a particular TCR, especially 
given the huge TCR repertoire and the high level of cross-
reactivity just from a probabilistic point of view alone. 45 It 
is also worthwhile to remember that the overwhelming 
majority of low molecular weight,  “ drug-like ” compounds 
known to bind to differing receptor classes act as antago-
nists. In analogy to these fi ndings, it seems likely that at 
least some drugs may not only activate but also block their 
(drug-specifi c) TCR. 
 THE P-I CONCEPT: DRUG REACTIVITY MASKING 
AS CROSS-REACTIVITY TO PEPTIDE ANTIGENS? 
 Even though the majority of drug-induced, T-cell-mediated 
skin reactions occur only after several days or even weeks 
of drug exposure, they can sometimes arise within a few 
hours after administration and/or without previous exposure 
to the drug (eg, documented for RCM). 38 , 39 RCM are admin-
istered in extremely high doses, which might partly explain 
this observation. However, and notwithstanding the excep-
tional amounts of drug, the kinetics of such a reaction are 
much too fast to be explained by the induction of a classical, 
primary response, which is a prerequisite of the hapten 
model, as primary responses are mounted in the course of 
several days. On the other hand, a secondary response of the 
immune system is generally much faster and can lead to an 
immune reaction within the time frame observed for some 
adverse drug reactions. The existence of peptide-specifi c, 
preactivated memory T cells already present in the circula-
tion and tissue that are cross-reactive to a particular drug 
seems an attractive explanation. If a sensitive individual 
harboring such cells were exposed to suffi cient concentra-
tions of the drug, these preactivated T cells would then be 
stimulated  “ accidentally ” and induce a fast and potentially 
vigorous response. In line with this notion is the observation 
that the vast majority of drug-specifi c TCC have been found 
to bear    TCR, which usually recognize peptides, and that 
a general stimulation of T cells, as in HIV infection, 46 is an 
important risk factor for drug hypersensitivity. Even more, 
it seems likely that drug-reactive cells exist even in individ-
uals that are not hypersensitive: in an in vitro study, several 
blood donors who had never been exposed to SMX never-
theless harbored SMX- and SMX-NO-specifi c cells in their 
T-cell repertoire. 47 
 Hence, 2 (yet unproven) hypotheses are inherent to the p-i 
concept, and experiments unambiguously determining 
whether or not drug binding to TCR molecules occurs and if 
TCR double-specifi c for a drug and a peptide exist are cur-
rently under way. If these experiments proved the p-i con-
cept to be correct, they would constitute an important step 
to show that it may truly be feasible to modulate T-cell-
mediated responses in an antigen-specifi c way by using 
drugs or other low molecular weight compounds. If the p-i-
concept is examined from a different angle, it becomes clear 
that direct binding of small compounds (such as drugs) to 
the TCR also implies that the TCR itself may constitute a 
potential drug target. The underlying assumption for this —
 namely, the wealth of pharmacological agents acting on 
many other classes of receptors that often have peptides or 
proteins as their  “ real, ” endogenous ligands — has already 
been touched upon in The P-I Concept: The TCR as the 
Antigen Binding Molecule? It seems possible, albeit proba-
bly not feasible at this time, that the  “ arsenal ” of modern 
drug technology could be used to fi nd small molecules that 
block or enhance a particular, antigen-specifi c response of 
clinical relevance. 
 NOVEL GENETIC FACTORS LINKED TO DRUG 
HYPERSENSITIVITY 
 The idiosyncratic nature of hypersensitivity reactions has 
prompted an intensive search for genetic factors explaining 
their occurrence in only a small subset of treated persons. 30 
In accordance with the (pro)hapten concept, the major 
emphasis was put on pharmacogenetic factors such as an 
altered metabolism, as the generation of a more reactive 
intermediate, able to modify autologous proteins, would 
have been the most stringent explanation for the occurrence 
of immunological side effects. However, associations of 
hypersensitivities with particular pharmacological geno-
types remained often tenuous and even controversial, 31 such 
as the slow acetylator phenotype reported to enhance the 
occurrence of side effects to SMX, 32 and the moderate asso-
ciation of certain TNF-  promoter polymorphisms with car-
bamazepine hypersensitivity. 33 
 More recent studies focusing on immunological rather than 
metabolic factors have now revealed surprisingly clear 
associations of certain drug hypersensitivity reactions with 
HLA-class I alleles. In ~5% of treated patients, abacavir 
causes a severe hypersensitivity reaction affecting multiple 
organs. The majority of these patients with drug hypersensi-
tivity carried the HLA-B*5701 allele. This association was 
strongest in Caucasians, 34 and the particular allele was pres-
ent in 94.4% of patients but in only 1.7% of controls. 35 Pos-
sibly even more striking is the association of carbamazepine 
treatment with the appearance of Stevens-Johnson syn-
drome in Han-Chinese carrying the HLA-B 1502 allele. 36 
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This association is stronger than any other described so far 
for any HLA marker with a disease. In another case-control 
association study, the same authors identifi ed HLA-B*5801 
as an important genetic risk factor for severe allopurinol-
induced cutaneous adverse reactions such as Stevens-
 Johnson syndrome and toxic epidermal necrolysis. 37 
 It is clear that such strong associations with HLA alleles 
support an important role for HLA molecules in drug hyper-
sensitivity, and they certainly seem to favor the hapten 
 concept at least for these drugs. However, although the 
association with HLA alleles is very strong, it is not a suffi -
cient explanation: many patients with HLA-B*5801 are 
exposed to allopurinol, yet they do not develop hypersen-
sitivity. 37 Caucasians do not show the association of 
HLA-B*5701 and carbamazepine hypersensitivity. 34 , 35 As 
reported by the authors of these studies, other factors located 
in this region of chromosome 6 may be important as well 
(eg, hsp 70 and other genes). Most hypersensitivity reac-
tions involve CD4+ T cells, which are MHC class II 
restricted. 3 Last, not the HLA complex but the TCR, as its 
counterpart, might be crucial for the reaction, as the positive 
and negative selection of T cells in the thymus is codeter-
mined by the autologous HLA molecules and peptides that 
can be presented, thus infl uencing the antigen repertoire of 
the individual patient. 
 CONCLUSIONS 
 Recent studies have shown surprisingly strong associations 
between particular MHC molecules and several drug-
 hypersensitivity reactions, lending further credence to the 
(pro)hapten concept. However, more and more in vitro stud-
ies imply that the (pro)hapten model as the sole molecular 
explanation for drug-induced hypersensitivity may not be 
suffi cient, and that other possibilities should be considered. 
In fact, evidence is accumulating that certain drugs are able 
to activate T cells in ways that differ not only from the hap-
ten model but also from other established concepts in immu-
nology. It is becoming increasingly evident that not all drugs 
need to act as haptens. As far as drugs are concerned, it may 
be useful to draw inspiration from concepts of classical 
pharmacology, which have been established for greatly dif-
fering receptor classes. The potential reward may not only 
be a better understanding of drug-induced hypersensitivity 
reactions, but also novel means for immunomodulatory 
therapies. 
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